Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma
Authors
Keywords
-
Journal
Hepatology International
Volume 14, Issue 1, Pages 80-95
Publisher
Springer Science and Business Media LLC
Online
2019-12-04
DOI
10.1007/s12072-019-10003-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Liver damage related to immune checkpoint inhibitors
- (2019) Naoshi Nishida et al. Hepatology International
- Goals and targets for personalized therapy for HCC
- (2019) Thomas Couri et al. Hepatology International
- Immunotherapy in hepatocellular carcinoma
- (2019) Luigi Buonaguro et al. Annals of Hepatology
- Clinical development of targeted and immune based anti-cancer therapies
- (2019) N. A. Seebacher et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110β and predicts poor prognosis
- (2019) Xiao-Lu Ma et al. Journal of Hematology & Oncology
- Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies
- (2019) Ivan Perrot et al. Cell Reports
- Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
- (2019) MinKe He et al. JAMA Oncology
- Clinical immunology and immunotherapy for hepatocellular carcinoma: current progress and challenges
- (2019) Lifeng Wang et al. Hepatology International
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Immune Evasion in Tumor’s Own Sweet Way
- (2018) Haidong Tang et al. Cell Metabolism
- Immune checkpoint therapy in liver cancer
- (2018) Feng Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- The hepatocellular carcinoma market
- (2018) Joshua Dawkins et al. NATURE REVIEWS DRUG DISCOVERY
- Viewing Siglecs through the lens of tumor immunology
- (2017) Isabella Fraschilla et al. IMMUNOLOGICAL REVIEWS
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression
- (2017) Jing Liao et al. Cancer Immunology Research
- Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
- (2016) Yi-Peng Fu et al. BRITISH JOURNAL OF CANCER
- IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8+T cells
- (2016) Alistair Noble et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Molecular targeted therapy for the treatment of gastric cancer
- (2016) Wenting Xu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CD169 identifies an anti-tumour macrophage subpopulation in human hepatocellular carcinoma
- (2016) Yi Zhang et al. JOURNAL OF PATHOLOGY
- Extracellular purines, purinergic receptors and tumor growth
- (2016) F Di Virgilio et al. ONCOGENE
- The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
- (2016) Meng Michelle Xu et al. TRENDS IN IMMUNOLOGY
- Regulation of the T Cell Response by CD39
- (2016) Maisa C. Takenaka et al. TRENDS IN IMMUNOLOGY
- Hepatocellular carcinoma
- (2016) Josep M. Llovet et al. Nature Reviews Disease Primers
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2015) et al. JOURNAL OF HEPATOLOGY
- Trial Watch: Radioimmunotherapy for oncological indications
- (2014) Norma Bloy et al. OncoImmunology
- T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
- (2013) Joel Crespo et al. CURRENT OPINION IN IMMUNOLOGY
- Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
- (2013) Mei-Ling Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD169+ macrophages at the crossroads of antigen presentation
- (2011) Luisa Martinez-Pomares et al. TRENDS IN IMMUNOLOGY
- CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens
- (2010) Kenichi Asano et al. IMMUNITY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now